Next Article in Journal
New Metabolites Isolated from a Laurencia obtusa Population Collected in Corsica
Next Article in Special Issue
Intraconversion of Polar Ginsenosides, Their Transformation into Less-Polar Ginsenosides, and Ginsenoside Acetylation in Ginseng Flowers upon Baking and Steaming
Previous Article in Journal
Synaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42
Previous Article in Special Issue
Hyperjaponol H, A New Bioactive Filicinic Acid-Based Meroterpenoid from Hypericum japonicum Thunb. ex Murray
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Article

Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3β Inhibitors

1
ADINACO Research Group, Department of Pharmacognosy, Faculty of Pharmacy, Charles University, 500 05 Hradec Králové, Czech Republic
2
Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, 500 05 Hradec Králové, Czech Republic
3
Department for Life Quality Studies, University of Bologna, 47921 Rimini, Italy
*
Author to whom correspondence should be addressed.
Molecules 2018, 23(4), 719; https://doi.org/10.3390/molecules23040719
Received: 15 February 2018 / Revised: 19 March 2018 / Accepted: 19 March 2018 / Published: 21 March 2018
(This article belongs to the Collection Bioactive Compounds)
Glycogen synthase kinase-3β (GSK-3β) is a multifunctional serine/threonine protein kinase that was originally identified as an enzyme involved in the control of glycogen metabolism. It plays a key role in diverse physiological processes including metabolism, the cell cycle, and gene expression by regulating a wide variety of well-known substances like glycogen synthase, tau-protein, and β-catenin. Recent studies have identified GSK-3β as a potential therapeutic target in Alzheimer´s disease, bipolar disorder, stroke, more than 15 types of cancer, and diabetes. GSK-3β is one of the most attractive targets for medicinal chemists in the discovery, design, and synthesis of new selective potent inhibitors. In the current study, twenty-eight Amaryllidaceae alkaloids of various structural types were studied for their potency to inhibit GSK-3β. Promising results have been demonstrated by alkaloids of the homolycorine-{9-O-demethylhomolycorine (IC50 = 30.00 ± 0.71 µM), masonine (IC50 = 27.81 ± 0.01 μM)}, and lycorine-types {caranine (IC50 = 30.75 ± 0.04 μM)}. View Full-Text
Keywords: Amaryllidaceae alkaloids; Alzheimer’s disease; glycogen synthase kinase-3β; masonine; caranine; 9-O-demethylhomolycorine Amaryllidaceae alkaloids; Alzheimer’s disease; glycogen synthase kinase-3β; masonine; caranine; 9-O-demethylhomolycorine
Show Figures

Graphical abstract

MDPI and ACS Style

Hulcová, D.; Breiterová, K.; Siatka, T.; Klímová, K.; Davani, L.; Šafratová, M.; Hošťálková, A.; De Simone, A.; Andrisano, V.; Cahlíková, L. Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3β Inhibitors. Molecules 2018, 23, 719. https://doi.org/10.3390/molecules23040719

AMA Style

Hulcová D, Breiterová K, Siatka T, Klímová K, Davani L, Šafratová M, Hošťálková A, De Simone A, Andrisano V, Cahlíková L. Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3β Inhibitors. Molecules. 2018; 23(4):719. https://doi.org/10.3390/molecules23040719

Chicago/Turabian Style

Hulcová, Daniela, Kateřina Breiterová, Tomáš Siatka, Kamila Klímová, Lara Davani, Marcela Šafratová, Anna Hošťálková, Angela De Simone, Vincenza Andrisano, and Lucie Cahlíková. 2018. "Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3β Inhibitors" Molecules 23, no. 4: 719. https://doi.org/10.3390/molecules23040719

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop